Emerging Therapies for Patients with Atopic Dermatitis
It’s an exciting time for new therapies in atopic dermatitis with several therapies recently approved or in late-stage development. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Baltimore dermatologist Dr. Shawn Kwatra, who outlined the new treatment options. From therapies that target IL-13 and IL-31 to JAK inhibitors, dermatology cl …
It’s an exciting time for new therapies in atopic dermatitis with several therapies recently approved or in late-stage development. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Baltimore dermatologist Dr. Shawn Kwatra, who outlined the new treatment options. From therapies that target IL-13 and IL-31 to JAK inhibitors, dermatology cl … Continue reading "Emerging Therapies for Patients with Atopic Dermatitis"
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. There’s a lot of nuance in diagnosing psoriasis in darker skin tones, according to Dr. Han. Learn three components to consider, and why you might want to introduce systemic therapies earlier in this … 
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we had the opportunity to learn about treating common nail disorders from Dr. Molly A. Hinshaw, MD, FAAD, Director of Nail Clinic, Section Chief of Dermatopathology, and Professor of Dermatology at the University of Wisconsin School of Medicine. Nail conditions can markedly decrease the quality of life for patients not only due to … 
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Shari Lipner, director of the Nail Division at the New York-Presbyterian Hospital/Weill Cornell Medical Center. Hear the results of Dr. Lipner’s retrospective study on time to diagnosis in patients with skin of color who have nail psoriasis. Find out why the clinical examination is especially important. Learn how derm … 
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 